All the news Showing 10 of 40 articles from: Antiviral therapyGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Switching to TAF improves safety in people with hepatitis B with kidney and bone risk factors Liz Highleyman / 04 May 2018 People with risk factors for tenofovir toxicity who switched from tenofovir disoproxil fumarate (TDF; Viread) to the new tenofovir alafenamide (TAF; Vemlidy) maintained hepatitis B virus (HBV) suppression and showed evidence of improved kidney and ... Treatment that interferes with viral assembly shows promise for hepatitis B Liz Highleyman / 18 December 2017 JNJ-56136379, an experimental drug that interferes with assembly of the hepatitis B virus (HBV) capsid, demonstrated potent antiviral activity in an early clinical trial, researchers reported at the recent 2017 AASLD Liver Meeting in ... RNA interference therapy lowers viral biomarker in people with hepatitis B Liz Highleyman / 14 December 2017 ARB-1467, a novel type of treatment for hepatitis B, reduced levels of hepatitis B surface antigen (HBsAg) when used alone, and it may play a role in combination therapy to cure the ... Immune modulator inarigivir looks promising for people with hepatitis B Liz Highleyman / 12 December 2017 Inarigivir, or SB 9200, an immune-modulating drug that has a dual mechanism of action against hepatitis B virus (HBV), reduced levels of HBV DNA, RNA and antigens, and potency was ... TAF for hepatitis B improves kidney function and bone loss Liz Highleyman / 30 November 2017 Tenofovir alafenamide (TAF) remains effective against hepatitis B virus (HBV) for 96 weeks, with no resistance detected, according to studies presented at the 2017 AASLD Liver Meeting last month in ... REP 2139 combination therapy leads to functional control of hepatitis B virus Liz Highleyman / 29 November 2017 A majority of people with chronic hepatitis B treated with a nucleic acid polymer (REP 2139 or REP 2165) plus tenofovir and pegylated interferon were able to achieve 'functional control' of hepatitis B ... Besifovir and tenofovir exalidex look promising as new hepatitis B drug Liz Highleyman / 04 May 2017 Two investigational nucleotide analogue antivirals were shown to be active against hepatitis B virus (HBV) with minimal potential for kidney and bone toxicity, researchers reported at the International Liver Congress last week in Amsterdam. ... EASL releases updated hepatitis B guidelines at International Liver Congress Liz Highleyman / 26 April 2017 The European Association for the Study of the Liver (EASL) presented revised clinical practice guidelines for the management of hepatitis B virus (HBV) infection – the first update since 2012 – during a ... Switching to TAF for hepatitis B improves kidney function and bone loss Liz Highleyman / 26 April 2017 People with hepatitis B who switched from the old tenofovir disoproxil fumarate (TDF) to the new tenofovir alafenamide (TAF) saw improvements in kidney function biomarkers and recovery of bone loss, researchers reported at ... Is better treatment reducing liver cancer among people with hepatitis B? Liz Highleyman / 23 February 2017 The incidence of hepatocellular carcinoma (HCC) appears to be decreasing and mortality improving among people with chronic hepatitis B treated with suppressive antiviral therapy, according to studies presented at the recent 2016 AASLD ... ← Prev1234Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive